| ²é¿´: 1768 | »Ø¸´: 5 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[½»Á÷]
¡¾ÇóÖú¡¿ÇóÖú¹ØÓÚÒÁÅËÁ¢ÍªµÄ˵Ã÷Êé
|
|||
| ¹úÍâ¹ØÓÚÒÁÅËÁ¢Íª±¾ÉíµÄÏà¹ØÎÄÏ×±¨µÀ£¬ËµÃ÷Ê鼰רÀû¾ù¿É¡£ÏÈлл´ó¼Ò£¡ |
» ²ÂÄãϲ»¶
ÖÐÒ©²Ä±ê׼Ŀ¼´óÈ«llp2026£¨º¬¸÷Ê¡ÊÐÖÐÒ©²ÄºÍÅÚÖÆ¹æ·¶£©
ÒѾÓÐ2È˻ظ´
õ£°·ÍÑÒÒõ£»ù
ÒѾÓÐ13È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ87È˻ظ´
¼û¿¯¿ìµÄÖÐÎĺËÐÄÆÚ¿¯
ÒѾÓÐ2È˻ظ´
Ò»Ö¾Ô¸ÌìÖÐÒ½ÖÐҩѧר˶£¬Ï£ÍûÓÐbÇøµÄÀÏʦ¿ÉÒÔ¿¼ÂÇÒ»ÏÂÎÒ
ÒѾÓÐ1È˻ظ´
µ÷¼Á
ÒѾÓÐ2È˻ظ´
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
26Ä격ʿÉêÇë
ÒѾÓÐ20È˻ظ´
ÇóÖú ±½Á×Áò°·JP
ÒѾÓÐ0È˻ظ´
100½ð±Ò °¢ÄªÎ÷ÁÖ¿ËÀάËá¼ØÆ¬BPÒ©µäÖÐÌáµ½µÄ¿ËÀάËá¾ÛºÏÎï¾ßÌå½á¹¹Ê½ÊÇɶ£¿
ÒѾÓÐ2È˻ظ´
ҩѧר˶É격
ÒѾÓÐ1È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
˫һÁ÷ÄϾ©Ò½¿Æ´óѧÕмÆËã»ú¡¢AI¡¢Í³¼Æ¡¢ÉúÎïÐÅÏ¢µÈ·½Ïò26Äê9ÔÂÈëѧ²©Ê¿
+1/95
ÎïÀíѧ µ÷¼Á
+1/90
»ªÄÏʦ·¶´óѧ£¨211£©²©Ê¿ÕÐÉú- µç×Ó¡¢×Ô¶¯»¯¡¢»úе¡¢ÉúÎïѧ¡¢ÎïÀíÏà¹Ø×¨Òµ
+2/38
¸Õ¸Õ¹¤×÷²»¾ÃµÄ¹Â¶À¸Ð
+1/36
Öйú¿ÆÑ§Ôºº¼ÖÝҽѧÑо¿Ëùñû½½¿ÎÌâ×éÕÐÆ¸²©Ê¿ºó
+1/35
°Ä´óÀûÑÇÎ÷°Ä´óѧ£¨UWA£©ÕŽðÇ¿¿ÎÌâ×éÕÐÊÕÈ«½±²©Ê¿Éú£¨»¯¹¤ÐÂÄÜÔ´·½Ïò£©
+1/32
2026Ä깤¿ÆË¶Ê¿µ÷¼Á-ÉϺ£´óѧȫ¹úÖØµãʵÑéÊÒÍŶÓ-²ÄÁÏÊý¾ÝÍÚ¾ò·½Ïò-Ñо¿Éú3-5ÈË
+1/30
26Ä격ʿ×Ô¼ö
+1/17
±±¾©Ä³Ñо¿ÔºÉúÎﻯѧÓë·Ö×ÓÉúÎïѧÏà¹Ø×¨ÒµÉêÇ뿼ºËÖÆ²©Ê¿ÕÐÉú£¨´º¼¾£©
+1/14
»¶ÓÉúÎïÓëÒ½Ò©¡¢Ò©Ñ§¡¢»¯Ñ§µÈÏà¹Ø×¨ÒµµÄͬѧ
+1/9
211/˫һÁ÷---ʯºÓ×Ó´óѧ---Óлú»¯Ñ§·½ÏòÕе÷¼ÁÉú
+1/9
ÐÂ¼ÓÆÂ¹úÁ¢´óѧҩѧϵ»¯Ñ§ÉúÎïѧ¿ÎÌâ×éÕÐPhD
+1/8
ÐÂ¼ÓÆÂ¹úÁ¢´óѧҩѧϵ»¯Ñ§ÉúÎïѧ¿ÎÌâ×éÕÐPhD
+1/7
26ÄêÉ격×Ô¼ö-¼ÆËã»úÊÓ¾õ
+1/5
2026¿¼ÑеÄͬѧ£¬·ÖÊý²»¹»£¿Ïëµ÷¼ÁÉϰ¶µÄͬѧ£¬À´¿´
+1/4
ÉîÛÚ´óѧ²ÌÐ˿ƿÎÌâ×鲩ʿºó¼°Ñо¿ÖúÀíÕÐÆ¸
+1/2
085404 270Çóµ÷¼Á£¬bÇøÇóµ¼Ê¦ÊÕÁô½ÓÊÜ¿çרҵ
+1/1
Öйú¿ÆÑ§ÔºµØÇò»¯Ñ§Ñо¿ËùÕпÆÑÐÖúÀí
+1/1
ÉϺ£½»Í¨´óѧ»¯Ñ§»¯¹¤Ñ§ÔºÕÅÖÇÌοÎÌâ×é³ÏƸ²©Ê¿ºó
+1/1
Top-88ϤÄá¿Æ¼¼´óѧÊý¾Ý¿ÆÑ§/AI ÕÐÊÕ2027ÄêÈëѧ У½± ²©Ê¿Éú1µ½2Ãû(¹ú¼ÊºÍ±¾µØÑ§Éú£©
+1/1
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
| Õâ¸öÒ©ÊDz»ÊÇÓÐÖйúµÄ¾§ÐÍרÀûºÍÓÃ;רÀû°¡£¿ |
4Â¥2011-05-11 17:03:04
yangjing561(½ð±Ò+4): 2011-01-14 16:07:03
|
Reference 1: Corbett, R.; Bordeau, K.J.; Helsley, G.C.; Szewczak, M.R.; Wilmot, C.A.; Chiang, Y.; Hartman, H.B.; Conway, P.G.; Glamkowski, E.J.; Strupczewski, J.T.; 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: Antipsychotic profile of iloperidone (HP 873). J Med Chem 1995, 38, 7, 1119-31. Reference 2: Strupczewski, J.T.; Helsley, G.C.; Chiang, Y.; Bordeau, K.J. (Aventis Pharmaceuticals, Inc.); N-(Aryloxyalkyl)heteroarylpiperidines and-heteroarylpiperazines, a process for their preparation and their use as medicaments. EP 0402644; JP 1991063263 . Reference 3: Strupczewski, J.T.; Helsley, G.C.; Chiang, Y.; Bordeau, K.J.; Glamkowski, E.J. (Aventis Pharmaceuticals, Inc.); Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics. EP 0542136; EP 0612318; EP 0730452; EP 0957102; EP 0959075; EP 0959076; EP 0963984; JP 1995501055; JP 1997511215; US 5364866; US 5776963; WO 9309102; WO 9511680 . Reference 4: Mucke, H.A.M.; Castaner, J.; Iloperidone. Drugs Fut 2000, 25, 1, 29. Reference 5: Strupczewski, J.T.; Allen, R.C.; Gardner, B.A. (Aventis Pharmaceuticals, Inc.); 3-(4-Piperidyl)-1,2-benzisoxazoles. US 4355037 . |
2Â¥2011-01-14 13:56:17
zsc
Ìú¸Ëľ³æ (СÓÐÃûÆø)
- DRDEPI: 1
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 6652.4
- Ìû×Ó: 230
- ÔÚÏß: 278.2Сʱ
- ³æºÅ: 309535
yangjing561(½ð±Ò+4): 2011-01-14 16:07:11
|
http://www.accessdata.fda.gov/sc ... =Search.DrugDetails FDAÏà¹Ø×ÊÁÏ£¬ËµÃ÷Êé ÈýÏîÖØÒªÏà¹Ø×¨Àû£¬µÚÒ»ÏîרÀû£¬ÉêÇëºÅ£º90103721.4£¬ÉêÇëÈÕ£º1990.05.19 רÀûµ½ÆÚʱ¼ä£º2010Äê05ÔÂ19ÈÕ£¬Ãû³Æ£ºN-(·¼Ñõ»ùÍé»ù)ÔÓ·¼»ùßÉ़°Ò»ÔÓ·¼»ùßÉàº,ËüÃǵÄÖÆ±¸·½·¨ÒÔ¼°ËüÃÇ×÷ΪҩÎïµÄÓ¦ÓᣵڶþÏîרÀû£¬ÉêÇëºÅ£º 00130979.X£¬ÉêÇëÈÕ£º1990.05.19 £¬×¨Àûµ½ÆÚʱ¼ä£º2010Äê05ÔÂ19ÈÕ£¬Ãû³Æ£ºN£(·¼Ñõ»ùÍé»ù)ÔÓ·¼»ùßÉ़°Ò»ÔÓ·¼»ùßÉàº,×÷ΪҩÎïµÄÓ¦ÓᣵÚÈýÏîרÀû£¬ÉêÇëºÅ£º94194302.X ÉêÇëÈÕ£º1994.10.27£¬×¨Àûµ½ÆÚʱ¼ä£º2014Äê10ÔÂ27ÈÕ£¬Ãû³Æ£º·¼ÔÓ»·»ùßßà¤Àà¡¢ßÁ¿©ÍéÀ༰ßßàºÀ༰Æä×÷Ϊ¿¹¾«Éñ²¡Ò©ºÍֹʹҩµÄÓÃ;¡£ http://www.drugfuture.com/fda/nda022192_001.html Õâ¸öÒ²¿ÉÒÔ |
3Â¥2011-01-14 14:07:11
¡ï
lk590(½ð±Ò+1): лл²ÎÓë 2011-09-13 12:44:36
lk590(½ð±Ò+1): лл²ÎÓë 2011-09-13 12:44:36
|
ÓÃ;µÄרÀûºÜ¶à£¬»¹ÓÐһƪÊÇÌáµ½¾§Ð͵ÄרÀûwo 2004006886A2 |
5Â¥2011-05-12 10:31:02













»Ø¸´´ËÂ¥
